Apr 08, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress ReactionsVIEW RELEASE
Apr 01, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home SettingVIEW RELEASE
Mar 27, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient SettingVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Apr 08, 2026 02:11 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.13
CHANGE
0.04 (3.67%)
